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ABSTRACT
Introduction: Shifting selected antiretroviral therapy
(ART) tasks from specialised healthcare workers to
those with shorter or less formal training has been
implemented in resource-limited settings to alleviate
critical shortages of human resources for health.
However, the specifics of shifting ART dispensing from
pharmacy to non-pharmacy personnel have not been
addressed in a systematic review, although this can
potentially increase access to ART. We will assess the
effects of shifting dispensing and distribution of ART
and adherence assessment from pharmacy to non-
pharmacy personnel in low and middle-income
countries.
Methods and analysis: We will search PubMed,
CENTRAL, EMBASE, WHO Global Health Library and
relevant grey literature for eligible controlled trials. Two
authors will screen the search output, select eligible
studies, assess risk of bias and extract data from
included studies, resolving discrepancies by discussion
and consensus. We will perform meta-analysis using
both fixed and random effects models, investigate
clinical and statistical heterogeneity, and assess our
confidence in the overall evidence using standard
Cochrane methods, including GRADE.
Ethics and dissemination: Only secondary data will
be included in this review and ethics approval is not
required. We will disseminate the review findings in
various scientific fora, including peer-reviewed
journals. The findings may help to inform policy
makers in defining the scope of work of healthcare
workers, and global recommendations for shifting the
dispensing and distribution of ART from pharmacy to
non-pharmacy personnel.
Trial registration number: CRD42015017034.
INTRODUCTION
Description of the condition
By March 2015, 15 million (40.7%) of the
estimated 36.9 million people living with
HIV (PLHIV) globally were receiving
antiretroviral therapy (ART).1 Combination
ART is effective for reducing HIV related
morbidity and mortality as well as preventing
HIV transmission.2 Initiating ARTearly in the
course of HIV infection has been associated
with better health outcomes, both at patient
and population levels.3 4 Scale-up of ART in
low and middle income countries has
averted more than 5 million deaths; however,
bottlenecks preventing universal access to
ART still exist. One challenge is the critical
shortage of human resources for health
(HRH), including for the delivery of essen-
tial HIV related pharmacy services.
The WHO recommends a minimum of
one pharmacist per 2300 population, but
most countries in low-resource settings such
as sub-Saharan Africa have not yet met this
target.5 In addition to the absolute shortage,
it is likely that there is an uneven distribution
of pharmacists in such settings, as is the case
with other specialist healthcare workers who
Strengths and limitations of this study
▪ To our knowledge, this is the first published
protocol of a systematic review that will investi-
gate the effects of task shifting from pharmacy
to non-pharmacy personnel for dispensing or
distributing antiretroviral therapy to patients
living with HIV.
▪ The protocol was written according to the
PRISMA-P (Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols)
recommendations.
▪ The review findings may help to inform antiretro-
viral therapy guidelines by the WHO.
▪ The possible weakness of the planned review
would be the limitations of included studies, for
example, high risk of bias and heterogeneity of
settings, designs and effects.
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tend to concentrate in urban areas and the private
sector, further aggravating the HRH shortage.6 For
instance in South Africa, which is home to the largest
number of PLHIV in any country in the world, in 2010
only 24% of registered pharmacists worked in the public
sector where 80% of the population received care.7
Description of the intervention
Studies and programme reports indicate that involve-
ment of pharmacy personnel in HIV care results in
improved patient outcomes. For instance, in the USA,
the use of a multidisciplinary team approach with phar-
macists assuming a central role in ART initiation, dis-
pensing and adherence counselling improved treatment
outcomes such as viral load, patient retention and medi-
cation adherence.8
The work of pharmacists includes supply manage-
ment, dispensing and distributing medications, promot-
ing adherence, identifying and preventing potential
medication-related issues, and monitoring and reporting
adverse events. In some settings, programmes have
implemented alternative models of pharmacy services
that shift selected tasks from pharmacy to non-pharmacy
personnel. Such alternative models could potentially
increase the number of health workers involved in ART
distribution, adherence counselling and patient educa-
tion, free more time for pharmacy personnel, support
the integration of ART in primary care settings, minim-
ise the number of facility visits for ART collection, and
reduce pharmacy queue waiting times for patients.9
However, the speciﬁcs of shifting ART related tasks
from pharmacy to non-pharmacy personnel have not yet
been addressed in a systematic review. We therefore plan
to synthesise the evidence for task shifting in pharmacy
services, where non-pharmacy personnel undertake ART
dispensing and distribution and medication adherence
counselling. For this systematic review, pharmacy person-
nel will include both pharmacists and pharmacy techni-
cians. Pharmacy technicians constitute an important
part of the pharmacy workforce in low and middle-
income countries: a survey of 26 low and middle-income
countries in 2011 revealed that pharmacy technicians
constitute 10% (Nigeria) to 70% (Pakistan) of the phar-
macy workforce.10
How the intervention might work
Within the last decade, several high HIV burden coun-
tries adopted task shifting strategies where nurses and
non-physician clinicians initiate and maintain ART.11
Although this has undeniably expanded access to ART, it
is also increasingly essential that long facility waiting
times and frequent facility visits to collect ART are
addressed to alleviate the burden of care, both for
patients and healthcare providers.12 13
Recent studies in Uganda, Kenya and Mozambique
have shown positive outcomes when non-health profes-
sionals (lay people) delivered ART at the community
level.14 In Mozambique the use of PLHIV for distributing
ART, monitoring adherence, reporting outcomes and
referring sick patients to health facilities yielded a reten-
tion rate of 97.5% among stable patients on ART.14 In a
cluster randomised trial in Uganda, the use of trained
community health workers produced comparable results
with facility-based ART programme in terms of patient
retention, viral load suppression and mortality rate.15
Similar ﬁndings were also obtained in Kenya and Uganda
when lay providers were engaged in ART delivery.15 16
Task shifting has therefore been seen as an achievable
solution to the critical human resource shortages for
scale-up of ART.17 While it is imperative to increase the
rate of recruitment and training of health workers as
well as improve working conditions to reduce attrition
and emigration, the HIV pandemic requires a more
urgent measure to address the critical skills shortage.18
Such measures may include shifting selected tasks
(including dispensing and distributing ART and adher-
ence counselling) from pharmacy to non-pharmacy per-
sonnel. The task shifting could free time for pharmacy
personnel to focus on more technical functions such as
supply management and pharmacovigilance.
Why this review is important
Previous systematic reviews of task shifting for increasing
ART access focused on clinical services where
nurses and non-clinician physicians provide care.11
Dependence on and shortages of pharmacists are also
key constraints on ART expansion, but the speciﬁcs of
task shifting for ART dispensing or distribution from
pharmacy to non-pharmacy personnel have not been
reviewed systematically. We will systematically review the
scientiﬁc literature and assess the efﬁcacy and safety of
task shifting models that use non-pharmacy personnel in
dispensing or distributing ART and assessing adherence
to treatment of HIV infection.
OBJECTIVE
The aim of this review is to evaluate the efﬁcacy and
safety of shifting dispensing and distribution of ART as
well as assessment of adherence from pharmacy to non-
pharmacy personnel.
METHODS
This review protocol has been registered in the PROSPERO
International Prospective Register of Systematic Reviews
(http://www.crd.york.ac.uk/PROSPERO), registration
number CRD42015017034.
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) and
non-RCTs, irrespective of whether allocation to interven-
tions occurred at the individual or cluster level.
Types of participants
Participants will be PLHIV receiving ART.
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Types of interventions
We will include studies that evaluate the shifting of
selected tasks from pharmacy personnel to non-pharmacy
personnel. The selected tasks include dispensing and dis-
tribution of ART and adherence assessment. Pharmacy
personnel will include both pharmacists and pharmacy
technicians. Non-pharmacy personnel may include (but
are not limited to) nurses, non-physician clinicians, and
lay providers such as patient peer groups, community
volunteers, PLHIV and community health committees.
Types of outcome measures
Primary outcomes
The primary outcome for this review is risk of death.
Secondary outcomes
Our secondary outcome measures include:
▸ Virological suppression
▸ Number of all-cause sick visits made to the health
facility, including for adverse events
▸ Loss to follow-up
▸ Adherence to ART (as measured within the study, eg,
pill counts, recall methods, digital methods)
▸ Acceptability to pharmacy personnel, non-pharmacy
personnel and patients
▸ Harm, including error rates.
Search methods for identification of studies
We will perform a comprehensive and exhaustive search
of electronic databases and conference proceedings in
an attempt to identify all relevant studies available by
the search date, regardless of language of publication or
publication status (published, unpublished, in press or
in progress).
Databases of peer-reviewed literature
We will search the following electronic databases, from 1
January 1996 to the search date:
▸ Cochrane Central Register of Controlled Trials
(CENTRAL)
▸ Excerpta Medica Database (EMBASE)
▸ PubMed
▸ ISI Web of Science (Science Citation index)
▸ WHO Global Health Library, which includes refer-
ences from AIM (AFRO), LILACS (AMRO/PAHO),
IMEMR (EMRO), IMSEAR (SEARO) and WPRIM
(WPRO).
Along with appropriate Medical Subject Heading
(MeSH) terms and relevant keywords, we will use the
Cochrane Highly Sensitive Search Strategy for identify-
ing reports of randomised controlled trials in
MEDLINE,19 and the Cochrane validated strategies for
identifying references relevant to HIV infection and
AIDS. To identify other study designs, the RCT string
will be omitted. The search strategy will be iterative in
that references of included studies will be searched for
additional references. See table 1 for our provisional
search strategy for electronic databases.
Conference databases
We will search conference abstract archives on the web
sites of the Conference on Retroviruses and
Opportunistic Infections (CROI), the International
AIDS Conference (IAC) and the International AIDS
Society Conference on HIV Pathogenesis, Treatment and
Prevention (IAS), for all available abstracts presented at
these conferences from 1996 to the search date.
Searching other resources
We will also search the references of relevant articles as
well as the WHO International Clinical Trials Registry
Platform (ICTRP) and Clinicaltrials.gov. We will contact
relevant experts or organisations who may be aware of
additional studies in this ﬁeld.
Data collection and analysis
We will base the methodology for data collection and
analysis on the guidance provided in the Cochrane
Handbook of Systematic Reviews of Interventions.19
Selection of studies for inclusion
Two authors will read and assess the abstracts of identi-
ﬁed publications for potentially eligible studies. We will
obtain full text articles for all abstracts judged by at least
one of the two authors, to be potentially eligible. Two
authors will independently inspect these potentially eli-
gible publications to establish the relevance of the
article to the review according to the pre-speciﬁed cri-
teria regarding study design, participants, interventions
and outcome measures.
Data extraction and management
Two authors will independently extract data into a pre-
piloted data extraction form. The following character-
istics will be extracted from each included study:
Study details: Complete citations of publications asso-
ciated with the study, start and end dates, location, study
design characteristics, type of facility involved, investiga-
tors, funding sources, recruitment, method of random-
isation, sequence generation, method of allocation
concealment, blinding of participants and personnel,
blinding of outcome assessment, length of follow-up,
losses to follow-up, withdrawals or drop-outs and other
relevant details.
Details of the intervention: training of the cadre of health
workers who were dispensing or distributing ART, what
training or other support or supervision they received
and other relevant details.
Details of participants: Trial inclusion and exclusion
criteria, numbers of participants entering the trial, sex,
clinical staging, CD4 count and other pertinent details.
Outcome details: Deﬁnitions of outcomes, details of how
outcomes were assessed, numerators and denominators
associated with each outcome, completeness of outcome
data, effect estimates reported and other relevant
outcome information.
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Assessment of risk of bias in included studies
We will assess the risk of bias in RCTs using the
Cochrane risk of bias assessment tool for randomised
studies.19 For non-RCT studies, we will use the Cochrane
Risk of Bias Assessment Tool for Non-Randomised
Studies of Interventions (ACROBAT-NRSI).20
Table 1 Proposed search strategy for electronic databases
ID Search terms
PubMed
#1 (task*[tiab] OR task-shifting[tiab] OR referr*[tiab] OR referral and consultation[mh] OR role*[tiab]) AND (health personnel
[mh] OR doctor[tiab] OR doctors[tiab] OR clinician[tiab] OR clinicians[tiab] OR physician[tiab] OR physicians[tiab] OR
“healthcare provider"[tiab] OR “healthcare providers"[tiab] OR “health care provider"[tiab] OR “health care providers"[tiab]
OR pharmac*[tiab] OR apothecar*[tiab] OR chemist*[tiab] OR dispensar*[tiab])
#2 randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[MeSH] OR random
allocation[MeSH] OR double-blind method[MeSH] OR single-blind method[MeSH] OR clinical trial[pt] OR clinical trials
[MeSH] OR (“clinical trial"[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw]))
OR random*[tw] OR research design[mh:noexp] OR prospective studies[MeSH] OR control*[tw] OR volunteer*[tw]) OR
observational[tw] OR non-random*[tw] OR nonrandom*[tw] OR before after study[tw] OR time series[tw] OR cohort*[tw]
OR cross-section*[tw] OR prospective*[tw] OR retrospective*[tw] OR research design[mh:noexp] OR follow-up studies
[MeSH] OR longitud*[tw] OR evaluat*[tiab] OR pre-post[tw] OR (pre-test[tw] AND post-test[tw]) NOT (animals[MeSH]
NOT human[MeSH])
#3 (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv
infect*[tiab] OR human immunodeficiency virus[tiab]OR human immune deficiency virus[tiab] OR human
immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*) AND(deficiency virus[tiab]))
OR acquired immunodeficiency syndromes[tiab] OR acquired immune deficiency syndrome[tiab] OR acquired
immuno-deficiency syndrome[ tiab] OR acquired immune-deficiency syndrome[ tiab] OR ((acquired immun*) AND
(deficiency syndrome[tiab])) or “sexually transmitted diseases, viral”[mh]) OR HIV[tiab] OR HIV/AIDS[tiab] OR
HIV-infected[tiab] OR HIV[title] OR HIV/AIDS[title] OR HIV-infected[title]
#4 (HAART[tiab] OR ART[tiab] OR cART[tiab] OR antiretroviral[tiab] OR anti-retroviral[tiab] OR anti-viral[tiab] OR antiviral
[tiab] OR “Antiretroviral Therapy, Highly Active"[Mesh])
#5 #1 AND #2 AND #3 AND #4
Scopus
(HIV OR HIV/AIDS OR AIDS OR “HUMAN IMMUNODEFICIENCY” OR “ACQUIRED IMMUNODEFICIENCY)” AND
TITLE-ABS-KEY (TASK-SHIFTING OR TASKSHIFTING OR (TASK* AND SHIFT*) OR TASK* OR (REFERR* AND
(NURSE* OR PHARMAC*))) AND TITLE-ABS-KEY (ANTIRETROVIRAL OR ANTI-RETROVIRAL OR ART OR CART OR
HAART) AND TITLE-ABS-KEY (RANDOM* OR RANDOMIZED OR RANDOMISED OR TRIAL OR COHORT* OR
GROUP* OR COMPAR* OR OBSERVATIONAL OR PROSPECTIVE* OR RETROSPECTIVE* OR “SYSTEMATIC
REVIEW” OR “META-ANALYSIS)”
Web of Science
(TS=(HIV OR HIV/AIDS OR AIDS OR “HUMAN IMMUNODEFICIENCY” OR “ACQUIRED IMMUNODEFICIENCY)” AND
TS=(TASK-SHIFTING OR TASKSHIFTING OR (TASK* AND SHIFT*) OR TASK* OR (REFERR* AND (NURSE* OR
PHARMAC*))) AND TS=(ANTIRETROVIRAL OR ANTI-RETROVIRAL OR ART OR CART OR HAART) AND TS=
(RANDOM* OR RANDOMIZED OR RANDOMISED OR TRIAL OR COHORT* OR GROUP* OR COMPAR* OR
OBSERVATIONAL OR PROSPECTIVE* OR RETROSPECTIVE* OR “SYSTEMATIC REVIEW” OR “META-ANALYSIS)”)
OR
(TI=(HIV OR HIV/AIDS OR AIDS OR “HUMAN IMMUNODEFICIENCY” OR “ACQUIRED IMMUNODEFICIENCY)” AND
TI=(TASK-SHIFTING OR TASKSHIFTING OR (TASK* AND SHIFT*) OR TASK* OR (REFERR* AND (NURSE* OR
PHARMAC*))) AND TI=(ANTIRETROVIRAL OR ANTI-RETROVIRAL OR ART OR cART OR HAART) AND TI=
(RANDOM* OR RANDOMIZED OR RANDOMISED OR TRIAL OR COHORT* OR GROUP* OR COMPAR* OR
OBSERVATIONAL OR PROSPECTIVE* OR RETROSPECTIVE* OR “SYSTEMATIC REVIEW” OR “META-ANALYSIS)”)
CENTRAL
HIV* OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR HIV INFECT* OR HUMAN IMMUNODEFICIENCY VIRUS OR
HUMAN IMMUNEDEFICIENCY VIRUS OR HUMAN IMMUNE-DEFICIENCY VIRUS OR HUMAN
IMMUNO-DEFICIENCY VIRUS OR HUMAN IMMUN* DEFICIENCY VIRUS OR ACQUIRED IMMUNODEFICIENCY
SYNDROME OR ACQUIRED IMMUNEDEFICIENCY SYNDROME OR ACQUIRED IMMUNO-DEFICIENCY
SYNDROME OR ACQUIRED IMMUNE-DEFICIENCY SYNDROME OR ACQUIRED IMMUN* DEFICIENCY
SYNDROME in Title, Abstract, Keywords and (TASK-SHIFTING OR TASKSHIFTING OR (TASK* AND SHIFT*) OR
TASK* OR (REFERR* AND (NURSE* OR PHARMAC*))) in Title, Abstract, Keywords and ANTIRETROVIRAL OR
ANTI-RETROVIRAL OR ART OR cART OR HAART in Title, Abstract, Keywords
WHO Global Health Library
(TASK-SHIFTING OR TASKSHIFTING OR (TASK* AND SHIFT*) OR TASK* OR (REFERR* AND (NURSE* OR
PHARMAC*)) AND (HIV* OR human immunodeficiency) AND (antiretroviral OR anti-retroviral))) OR (HIV AND
task-shifting) OR (HIV* AND task* AND shift*)
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We will resolve any disagreements between the authors
conducting duplicate independent screening of search
outputs, assessments of study eligibility, extraction of
data, and risk of bias assessment by discussion and con-
sensus. Should this fail to resolve the differences, a third
author will arbitrate.
Measures of effect
We will calculate and report risk ratios for dichotomous
and time-to-event data and mean differences for con-
tinuous data with their 95% CIs.
Unit of analysis issues
The unit of analysis will be the individual study partici-
pant. Cluster-randomised trials will be included in
meta-analyses only after adjustments are made for
design effect. Design effects for cluster-randomised
studies will be corrected by using standard procedures,
using the formula: design effect=1+(m−1)r, where m is
the average cluster size and r is the intra-cluster correl-
ation coefﬁcient.
Dealing with missing data
We will contact study authors if it is necessary to obtain
data missing from published reports.
Assessment of heterogeneity
We will examine statistical heterogeneity between study
results using the χ2 test of homogeneity, with a signiﬁ-
cance α-level of 0.1. In addition, we will use the I2 stat-
istic to measure the amount of heterogeneity among
the trials in each analysis. If we identify signiﬁcant het-
erogeneity (ie, p<0.1), we will explore it by pre-
speciﬁed subgroup analysis. If heterogeneity persists,
we will perform sensitivity analyses, report results separ-
ately and propose reasons for the observed
heterogeneity.
Assessment of reporting biases
If any meta-analysis in our review includes 10 or more
studies, we will assess the potential for publication bias
using a funnel plot.21 We will attempt to minimise the
potential for publication bias through a comprehensive
search of published and unpublished literature.
Data synthesis
We will conduct meta-analysis, if appropriate, using the
Cochrane Review Manager software (RevMan
[Computer program] The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, 2015; Version 5.3). If
we ﬁnd no signiﬁcant statistical heterogeneity of effects,
we will use the ﬁxed effect method of meta-analysis.
Otherwise, we will use the random effects model.
Subgroup analysis
In pooled results with signiﬁcant statistical heterogeneity,
we will explore the cause of the heterogeneity through
subgroup analyses, with subgroups deﬁned by type of
intervention (eg, cadre of health provider), comparison
group and region of study (eg, sub-Saharan Africa,
Southeast Asia, etc).
Sensitivity analysis
We will conduct a sensitivity analysis to investigate the
effect of excluding studies with high risk of bias, with a
focus on bias introduced by inadequate allocation con-
cealment, inadequate blinding of outcome assessment
and substantial losses to follow-up.
Certainty of evidence
We will assess the certainty (or quality) of evidence using
the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) approach,22
which deﬁnes the certainty of evidence for each
outcome as “the extent of our conﬁdence that the esti-
mates of effect are correct”.19 The quality rating across
studies has four levels: high, moderate, low and very low.
Randomised trials are considered to be of high quality
but can be downgraded for any of ﬁve reasons: risk of
bias, indirectness of evidence, unexplained heterogen-
eity of effects, imprecision of effect estimates and high
probability of publication bias. Similarly, observational
studies are considered to be of low quality, but can be
upgraded for any of three reasons. The quality level of a
body of evidence can be increased if there is a large
magnitude of effect, if all plausible confounding would
reduce a demonstrated effect, and if there is a
dose-response gradient.
Reporting of this review
The ﬁndings of this review will be presented in a
number of ways. The study selection process will be
summarised using a ﬂow diagram, and if we identify 10
or more eligible studies, we will assess publication bias
using funnel plots. Where appropriate, we will use risk
of bias graphs, forest plots and GRADE summary of
ﬁndings tables. The non-quantitative outcomes will be
reported descriptively. We will provide tables of both
included and excluded studies. We have prepared this
protocol as recommended by the PRISMA-P (Preferred
Reporting Items for Systematic Review and
Meta-Analysis Protocols) guidelines23 and will report the
ﬁndings of the review as recommended by the PRISMA
statement.24
ETHICS AND DISSEMINATION
Since systematic reviews do not directly involve human
participants, they do not require ethical clearance.25 We
will provide the ﬁndings of this review to the WHO, with
the hope that they may guide policy recommendations
of this normative agent regarding the shifting of ART
dispensing or distribution from pharmacy to non-
pharmacy personnel. Although the majority of national
programmes in low and middle-income countries have
adopted task shifting in ART care at different levels,
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there has been no global policy to guide the practice for
task shifting from pharmacy to non-pharmacy personnel.
We will also publish the ﬁndings of the systematic review
in a peer-reviewed journal.
Twitter Follow Charles Wiysonge at @CharlesShey
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